According to Frost & Sullivan’s Aiswariya Chidambaram, the European CMO sector is set to double in the next six years. Revenues are said to hit $20.75 billion. The reason for this growth stem from the increasing incidence of generics and companies who will leverage CMOs (Contract manufacturing Organizations) once their drugs are out of patent. Aiswariya Chidambaram added that with the expected growth, European CMOs should still be cautious, “Its tricky…It’s where anticipating demand comes into play. There are a lot of factors that could affect demand for certain markets, for instance the product requirements the approvals rates by regulatory bodies or the new technologies”. To read more, click here.
Obstacles Facing Biosimilars
Still in its infancy in the U.S., the industry faces some growing pains.
Life Science Accelerated
Our experts are dedicated to expediting life science product development regulatory pathways.